ASH 2023 | Responses in R/R MM treated with teclistamab following prior BCMA-directed therapy
Ariel Grajales-Cruz, MD, Moffitt Cancer Center, Tampa, FL, discusses the safety and efficacy of teclistamab in patients with relapsed/refractory (R/R) multiple myeloma (MM) who were previously treated with a B-cell maturation antigen (BCMA)-targeted therapy. A recent single-center study aimed to address disease outcomes in these patients, as BCMA pre-treated patients were excluded from the analysis of the MajesTEC-1 trial of teclistamab (NCT04557098), leading to a lack of data regarding outcomes in this group. Encouragingly, the outcomes in this patient population were comparable to those seen in MajesTEC-1. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Speakers Bureau: Amgen, Sanofi
Board of Directors/Advisory Committee: Sanofi, Cellectar, Janssen
